Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-11-18 Sale |
2024-11-20 5:00 pm |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
137,803 | $0.2103 | $28,980 | 0 (Direct) |
View |
| 2024-09-10 Purchase |
2024-09-12 5:00 pm |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
100,000 | $1.6124 | $161,240 | 124,552 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-10-31 Exercise |
2024-11-04 5:01 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
18,875 | $0 | 137,803 (Direct) |
View |
| 2024-10-31 Tax Withholding |
2024-11-04 5:01 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
5,624 | $2.09 | 137,803 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-18 9:26 pm |
N/A 2034-06-14 |
LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director |
6,696 | $0 | 10,841 (Direct) |
View |
| 2024-03-31 Exercise |
2024-04-02 4:54 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
15,333 | $0 | 55,219 (Direct) |
View |
| 2024-04-01 Tax Withholding |
2024-04-02 4:54 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
4,732 | $5.12 | 55,219 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:53 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
18,875 | $0 | 32,826 (Direct) |
View |
| 2023-11-01 Tax Withholding |
2023-11-02 4:53 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
6,301 | $2.22 | 32,826 (Direct) |
View |
| 2023-06-09 Option Award |
2023-06-13 6:53 pm |
N/A 2033-06-09 |
LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director |
6,603 | $0 | 9,606 (Direct) |
View |
| 2023-03-31 Exercise |
2023-04-04 6:57 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
2,000 | $0 | 7,377 (Direct) |
View |
| 2023-04-03 Tax Withholding |
2023-04-04 6:57 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
623 | $2.58 | 7,377 (Direct) |
View |
| 2023-02-16 Option Award |
2023-02-21 4:21 pm |
N/A N/A |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2022-10-06 Option Award |
2022-10-11 4:37 pm |
N/A 2032-10-05 |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
87,500 | $0 | 87,500 (Direct) |
View |
| 2022-06-29 Option Award |
2022-06-30 6:32 pm |
N/A 2032-06-29 |
LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director |
7,657 | $0 | 7,657 (Direct) |
View |
| 2022-02-15 Option Award |
2022-02-17 4:07 pm |
N/A 2032-02-14 |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
205,000 | $0 | 205,000 (Direct) |
View |
| 2021-10-12 Option Award |
2021-10-13 4:06 pm |
N/A 2031-10-11 |
Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer |
750,000 | $0 | 750,000 (Direct) |
View |